{"schema_version":"secwatch.filing_event.v1","accession":"0001161697-21-000572","form_type":"8-K","ticker":"KRMD","cik":"0000704440","company_name":"KORU Medical Systems, Inc.","filed_at":"2021-12-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:15.303932+00:00","generated_at":"2026-06-28T02:13:50.269698+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"KORU Medical expects FY2021 revenue $23.0M-$23.2M; Q4 to show sequential growth","bullets":["Q4 2021 expected to be the fourth consecutive quarter of positive sequential revenue growth.","Full year 2021 revenue guidance of $23.0 million to $23.2 million.","Domestic SCIg market expected to recover to mid-to-high single digits in 2022.","Company expects its domestic SCIg revenue growth to be slightly ahead of the market recovery."],"urls":{"canonical":"https://secwatch.observer/filing/0001161697-21-000572","json":"https://secwatch.observer/filing/0001161697-21-000572.json","markdown":"https://secwatch.observer/filing/0001161697-21-000572.md","text":"https://secwatch.observer/filing/0001161697-21-000572.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/704440/000116169721000572/0001161697-21-000572-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/704440/000116169721000572/form_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T02:13:50.269698+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}